Targeting virus entry and membrane fusion through specific peptide/MHC complexes using a high-affinity T-cell receptor

Gene Therapy

Volumn 11, Issue 15, 2004, Pages 1234-1239

  Peng, K W ^a   Holler, P D ^b,c   Orr, B A ^b   Kranz, D M ^b   Russell, S J ^a  

^a Mayo Clinic   (United States)

^b UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^c MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Measles virus; Peptide MHC complexes; Single chain TCR; Targeting

Indexed keywords

LIGAND; PEPTIDE FRAGMENT; T LYMPHOCYTE RECEPTOR; VIRUS PROTEIN; HYBRID PROTEIN; LYMPHOCYTE ANTIGEN RECEPTOR;

ARTICLE; CELL SURFACE; COMPLEX FORMATION; CONTROLLED STUDY; GENE EXPRESSION; GENE TARGETING; GENETIC ENGINEERING; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MEASLES VIRUS; MEMBRANE FUSION; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; TARGET CELL; VIRUS ATTENUATION; VIRUS CELL INTERACTION; VIRUS INFECTIVITY; ANIMAL; CELL MEMBRANE; CERCOPITHECUS; GENE THERAPY; GENETICS; METABOLISM; METHODOLOGY; MOUSE; T CELL LYMPHOMA; TUMOR CELL LINE; VERO CELL; VIRUS DNA CELL DNA INTERACTION;

MEASLES VIRUS;

ANIMALS; CELL LINE, TUMOR; CELL MEMBRANE; CERCOPITHECUS AETHIOPS; GENE THERAPY; HUMANS; LIGANDS; LYMPHOMA, T-CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MEASLES VIRUS; MEMBRANE FUSION; MICE; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; VERO CELLS; VIRUS INTEGRATION;

EID: 4243139564     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302286     Document Type: Article

References (37)

1. Rudolph MG, Wilson IA. The specificity of TCR/pMHC interaction. Curr Opin Immunol 2002; 14: 52-65.
2. Antoniou AN, Powis SJ, Elliott T. Assembly and export of MHC class I peptide ligands. Curr Opin Immunol 2003; 15: 75-81.
3. Germain RN, Stefanova I. The dynamics of T cell receptor signaling: complex orchestration and the key roles of tempo and cooperation. Annu Rev Immunol 1999; 17: 467-522.
4. Germain RN. The T cell receptor for antigen: signaling and ligand discrimination. J Biol Chem 2001; 276: 35223-35226.
5. Santana MA, Rosenstein Y. What it takes to become an effector T cell: the process, the cells involved, and the mechanisms. J Cell Physiol 2003; 195: 392-401.
6. Sadelain M, Riviere I, Brentjens R. Targeting tumours with genetically enhanced T lymphocytes. Nat Rev Cancer 2003; 3: 35-45.
7. Denkberg G et al. Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen. J Immunol 2003; 171: 2197-2207.
8. Schumacher TN. T-cell-receptor gene therapy. Nat Rev Immunol 2002; 2: 512-519.
9. Schlueter CJ, Schodin BA, Tetin SY, Kranz DM. Specificity and binding properties of a single-chain T cell receptor. J Mol Biol 1996; 256: 859-869.
10. Chen J, Eisen HN, Kranz DM. A model T-cell receptor system for studying memory T-cell development. Microbes Infect 2003; 5: 233-240.
11. Dorig RE, Marcil A, Chopra A, Richardson CD. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 1993; 75: 295-305.
12. Tatsuo H, Ono N, Tanaka K, Yanagi Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature 2000; 406: 893-897.
13. Grote D et al. Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice. Blood 2001; 97: 3746-3754.
14. Peng KW et al. Systemic therapy of myeloma xenografts by an attenuated measles virus. Blood 2001; 98: 2002-2007.
15. Peng KW et al. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. Cancer Res 2002; 62: 4656-4662.
16. Peng KW et al. Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides. Nat Med 2002; 8: 527-531.
17. Schneider U et al. Recombinant measles viruses efficiently entering cells through targeted receptors. J Virol 2000; 74: 9928-9936.
18. Peng KW et al. Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker. Blood 2003; 101: 2557-2562.
19. Hammond AL et al. Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J Virol 2001; 75: 2087-2096.
20. Bucheit AD et al. An oncolytic measles virus engineered to enter cells through the CD20 antigen. Mol Ther 2003; 7: 62-72.
21. Holler PD, Chlewicki LK, Kranz DM. TCRs with high affinity for foreign pMHC show self-reactivity. Nat Immunol 2003; 4: 55-62.
22. Holler PD, Kranz DM. Quantitative analysis of the contribution of TCR/pepMHC affinity and CD8 to T cell activation. Immunity 2003; 18: 255-264.
23. Garcia KC et al. Alphabeta T cell receptor interactions with syngeneic and allogeneic ligands: affinity measurements and crystallization. Proc Natl Acad Sci USA 1997; 94: 13838-13843.
24. Sykulev Y et al. Peptide antagonism and T cell receptor interactions with peptide-MHC complexes. Immunity 1998; 9: 475-483.
25. Buchholz CJ et al. In vivo selection of protease cleavage sites from retrovirus display libraries. Nat Biotechnol 1998; 16: 951-954.
26. Firsching R et al. Measles virus spread by cell-cell contacts: uncoupling of contact-mediated receptor (CD46) downregulation from virus uptake. J Virol 1999; 73: 5265-5273.
27. Reay PA et al. Determination of the relationship between T cell responsiveness and the number of MHC-peptide complexes using specific monoclonal antibodies. J Immunol 2000; 164: 5626-5634.
28. Kageyama S, Tsomides TJ, Sykulev Y, Eisen HN. Variations in the number of peptide-MHC class I complexes required to activate cytotoxic T cell responses. J Immunol 1995; 154: 567-576.
29. Christinck ER, Luscher MA, Barber BH, Williams DB. Peptide binding to class I MHC on living cells and quantitation of complexes required for CTL lysis. Nature 1991; 352: 67-70.
30. Irvine DJ, Purbhoo MA, Krogsgaard M, Davis MM. Direct observation of ligand recognition by T cells. Nature 2002; 419: 845-849.
31. Purbhoo MA et al. The human CD8 coreceptor effects cytotoxic T cell activation and antigen sensitivity primarily by mediating complete phosphorylation of the T cell receptor zeta chain. J Biol Chem 2001; 276: 32786-32792.
32. Lavillette D, Russell SJ, Cosset FL. Retargeting gene delivery using surface-engineered retroviral vector particles. Curr Opin Biotechnol 2001; 12: 461-466.
33. Hatziioannou T et al. Retroviral display of functional binding domains fused to the amino terminus of influenza hemagglutinin. Hum Gene Ther 1999; 10: 1533-1544.
34. Ohno K et al. Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A. Nat Biotechnol 1997; 15: 763-767.
35. Cho BK et al. A proposed mechanism for the induction of cytotoxic T lymphocyte production by heat shock fusion proteins. Immunity 2000; 12: 263-372.
36. Duprex WP et al. Observation of measles virus cell-to-cell spread in astrocytoma cells by using a green fluorescent protein-expressing recombinant virus. J Virol 1999; 73: 9568-9575.
37. Radecke F et al. Rescue of measles viruses from cloned DNA. EMBO J 1995; 14: 5773-5784.